Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. For more, please visit: bicara.com.

Biocon

Omega Funds

RA Capital Management

Bioqube Ventures

Invus

Janus Henderson Investors

Aisling Capital

Piper Heartland Healthcare Capital

PremjiInvest

Braidwell

Deerfield Management

Eight Roads Ventures

F-Prime Capital

Fairmont Capital

The Rise Fund

Bicara Therapeutics

Viewport Meta

IPhone / Mobile Compatible

SSL by Default

Euro

Google Tag Manager

HSTS

Google Analytics

WordPress

Global Site Tag

Finance and Administration

Ivan Hyep

Chief Medical Officer

Liviu Niculescu

Operations

David Bohr

Senior Vice President, R&D Strategy & Operations

Rachel Salazar

VP, Technical Operations & Supply Chain

Sathish Hasige

Associate Director, Clinical Operations

Allen Lau

Healthcare

Elham Gharakhani

Sr. Director, Head of Data Mangement

Marie Bonneau

Olger Bostanxhi

Ralf Reiners

Ketan Patel

Jake Simson

Krishna Polu

Scott Robertson

Seng-Lai "Thomas" Tan

Ryan Cohlhepp

President & Chief Operating Officer

David Raben

Claire Mazumdar

Founding CEO

New England Companies With More Than 10 Employees (Top 10K)

Northeastern US Companies With More Than 10 Employees (Top 10K)

Massachusetts Companies With Fewer Than 1000 Employees (Top 10K)

Massachusetts Companies With More Than 10 Employees (Top 10K)

Bicara Therapeutics is a clinical-stage biotechnology startup focused on developing dual-action biologics. The business is developing bifunctional antibodies that are designed to deliver an immunomodulatory payload directly to the tumor microenvironment, assisting cancer patients in increasing immune cell activity and potentially providing long-term efficacy.

Series C - Bicara Therapeutics

Red Tree Venture Capital

Series B - Bicara Therapeutics

Seed Round - Bicara Therapeutics

Cambridge

Massachusetts

United States

North America

Bicara Therapeutics initiated with a Not Rated at Goldman Sachs

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

Bicara Therapeutics initiated with bullish view at Morgan Stanley, here's why

North American Startup Funding Weakened In Q3 As Largest Deal Took Longer To Close

Bicara Therapeutics Files for IPO

Bicara Therapeutics Picks Morgan Stanley For IPO of Up to $150 Million

Bicara Therapeutics picks Morgan Stanley for IPO of up to $150m.

Billionaire-Backed Cancer Researcher Claire Mazumdar Finds Entrepreneurial Niche

A dual-action bifunctional antibody designed to inhibit EGFR and disable TGF-β directly at the tumor site, currently in clinical trials for multiple cancer types.

A bispecific antibody targeting tumor antigen CAIX conjugated to an attenuated IL-12, demonstrating pre-clinical efficacy with potential for limited systemic toxicity.

India

Asia

United Kingdom

Europe

ZoomInfo provides comprehensive data on companies, including location, revenue, and industry information.

ZoomInfo

Talkdesk offers contact center and collaboration tools for internal communication, as well as AI for customer experience analytics.

Talkdesk

Talkwalker provides social listening, media monitoring, and social benchmarking platform for analyzing social and consumer data.

Talkwalker

Bicara Inc. is a technology-driven company that specializes in providing innovative communication solutions and data analytics services to businesses across various industries. The company leverages cutting-edge technology to enhance customer engagement and provide actionable insights for decision-making.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

Bicara Therapeutics Inc. Common Stock

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 14, 2024 12:13 PM	d8075907
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	0c016985
crunchbase profile	general	Nov 22, 2024 9:29 AM	2446ceae
li profile	general	May 14, 2024 12:13 PM	c3a23d28
translate crunchbase fundingrounds	general	Nov 22, 2024 2:02 PM	c1240f5f
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

BCAX

COM:BICARA

Bicara Inc.

Last Close

17.77

22/11 21:00

Market Cap

802.06M

Beta: -

Volume Today

414.23K

Avg: -